Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Is a pre-menopausal female, between 18 and 47 years~* Participant has a history of at least 3 regular menstrual cycles in which menorrhagia (heavy bleeding) is due to uterine fibroids~* Confirmed uterine fibroid(s) at screening~* Visit 1 historical pictorial blood loss assessment chart of \>120 milliliters (mL) of blood loss, to ensure participants have a menstrual blood loss of at least 80 mL by Alkaline Hematin Assay (during the baseline assessment period).~* A Body Mass Index (BMI) between 18 and 45 inclusive~Exclusion Criteria:~* Participant is pregnant or lactating or is attempting or expecting to become pregnant during the entire study period~* Received an investigational drug in the 30 days prior to the screening for this study~* Has an intrauterine device in place~* Observation or history of abnormal endometrial biopsy including the presence of endometrial intraepithelial neoplasia~* Participants with abnormally high liver enzymes or liver disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 47 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
- Telapristone Acetate 6 mg (Type: EXPERIMENTAL): Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
- Telapristone Acetate 12 mg (Type: EXPERIMENTAL): Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.

Based on this trial design, predict the completion outcome and termination type (if applicable).